

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box PCT, Commissioner for Patents, Washington, D.C. 20231 on 4/15/02.

By: [Signature] Printed: Margaret M. Hasson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: PHOSPHORYLATION EFFECTORS

Serial No.: 09/744,794

Filing Date:

To Be Assigned

Examiner: To Be Assigned

Group Art Unit:

To Be Assigned

Box PCT

Commissioner for Patents

Washington, D.C. 20231

**RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE
AND AMENDMENT DIRECTING ENTRY INTO THE SPECIFICATION**

Sir:

This paper is in response to the Notification of Defective Response mailed on March 13, 2002 for which a response is due on April 15, 2002.

Applicants submit this amendment to request entry of the enclosed paper copy of the sequence listing from International Application Number PCT/US99/17132 into the above-identified U.S. national phase patent application.

Applicant(s) submit the document(s) listed below to complete the filing for the above-identified patent application.

1. A Substitute Computer Readable Form (CRF) of the "Sequence Listing" of the above-identified USN application;
2. Submission Under 37 CFR § 1.821 - 1.825 Sequence Listing (1 pg.);
3. A substitute paper copy of the "Sequence Listing" (64 pp.);
4. A copy of PTO form PCT/DO/EO/916 (371 Formalities Notice); and
5. A return receipt postcard.

In the Notification, the Office of Initial Patent Examination has requested a replacement sequence listing and an amendment directing its entry into the specification – where it already exists and has since the initial PCT filing. These actions are not understood.

Applicant's do not believe a fee is due with this filing. However, if the Patent Office deems that a fee is due, please charge Deposit Account No. **09-0108**.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,
INCYTE GENOMICS, INC.

Date: 15 April 2002

D. Hamlet-Cox

Diana Hamlet-Cox

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886

MAR 19 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box 801
United States Patent and Trademark Office
Washington, D.C. 20233
www.uspto.gov

U.S. APPLICATION NUMBER NO 09744794	FIRST NAMED APPLICANT Jennifer L. Hillman	ATTY DOCKET NO PF-0565 USN
INTERNATIONAL APPLICATION NO PCT/US99/17132		
IA FILING DATE 07/28/1999		PRIORITY DATE 07/28/1998

Incyte Genomics
3160 Poter Drive
Palo Alto, CA 94304

CONFIRMATION NO. 4717

371 FORMALITIES LETTER



OC000003007625602

Due 4/13/02

Date Mailed: 03/13/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Assignee Statement
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - does not identify the application to which it is directed.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

CHARITTA A BURT

Telephone: (703) 305-3734

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO	INTERNATIONAL APPLICATION NO	ATTY DOCKET NO
09/744,794	PCT/US99/17132	PF-0565 USN

Box PCT
Commissioner for Patents
Washington, D.C. 20231

Mailed: April 15, 2002
Docket No.: PF-0565 USN

Applicants: Hillman et al.
Serial No.: 09/744,794
Filing Date: To Be Assigned
Title: **PHOSPHORYLATION EFFECTORS**

Enclosed are:

1. Return Receipt Postcard;
2. Response to Notification of Defective Response and Amendment Directing Entry Into Specification (2 pp.);
3. A substitute Computer Readable Form (CRF) of the "Sequence Listing";
4. A substitute paper copy of the "Sequence Listing" (64 pp.); and
5. A copy of PTO form PCT/DO/EO/916 (371 Formalities Notice).

J002 BOLD PCT/PTO 2 2 APR 2002

Method of Payment: Deposit Account

DHC/mmh